In the past 12 months, the company’s shares have gained 167% and the company has reached a RON2.2 billion capitalization.
Net turnover (revenues from contracts with clients) achieved between January and September 2024 amounted to 506.05 million lei, of which the net turnover recorded in the Romanian market amounted to 303.79 million lei, by 5% above the level achieved in the same period of the previous year.
The increase came as a „favorable effect of redefining the way of working with the distributors and national chains in Romania, the main objectives being the increase in the market share correlated with the sales potential of the products in each of the pharma market segments, respectively : hospital, pharmacy chains and smallchains and independent pharmacies”.
The net turnover recorded in the international market amounted to 202.26 million lei, by 16% higher than that recorded in the same period of the previous year.
Revenues from the sale of finite products reached RON130.4 million, up 20% from the year-earlier period.
With a view to durable development, the company in the first nine months of 2024 carried out total investments of RON78.5 million, 50% higher than in the same period of 2023.
(English version by Catalina Apostoiu)